Does the media favor REGN or AMGN?

In the previous week, Regeneron Pharmaceuticals had 43 more articles in the media than Amgen. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 54 mentions for Amgen. Amgen's average media sentiment score of 1.07 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 38 Very Positive mention(s) 8 Positive mention(s) 37 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive Amgen 33 Very Positive mention(s) 8 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer GILD or REGN?

In the previous week, Regeneron Pharmaceuticals had 44 more articles in the media than Gilead Sciences. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 53 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.96 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 33 Very Positive mention(s) 7 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Regeneron Pharmaceuticals 38 Very Positive mention(s) 8 Positive mention(s) 37 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to REGN or MRNA?

In the previous week, Regeneron Pharmaceuticals had 61 more articles in the media than Moderna. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 36 mentions for Moderna. Moderna's average media sentiment score of 0.70 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 38 Very Positive mention(s) 8 Positive mention(s) 37 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive Moderna 12 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NTLA or REGN?

In the previous week, Regeneron Pharmaceuticals had 93 more articles in the media than Intellia Therapeutics. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 4 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.68 beat Intellia Therapeutics' score of 0.63 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 38 Very Positive mention(s) 8 Positive mention(s) 37 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer VIR or REGN?

In the previous week, Regeneron Pharmaceuticals had 90 more articles in the media than Vir Biotechnology. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 7 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.14 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 38 Very Positive mention(s) 8 Positive mention(s) 37 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive

Regeneron Pharmaceuticals (REGN) Competitors

$762.63 +24.29 (+3.29%)

Closing price 04:00 PM Eastern

Extended Trading

$754.30 -8.34 (-1.09%)

As of 04:39 PM Eastern

Compare

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

Should you buy Regeneron Pharmaceuticals stock or one of its competitors? MarketBeat compares Regeneron Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), and Vir Biotechnology (VIR).

How does Regeneron Pharmaceuticals compare to Amgen?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Regeneron Pharmaceuticals currently has a consensus price target of $794.83, indicating a potential upside of 4.22%. Amgen has a consensus price target of $357.00, indicating a potential downside of 7.31%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

Regeneron Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$15.53B	5.19	$4.50B	$40.46	18.85
Amgen	$36.75B	5.66	$7.71B	$14.37	26.80

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 43 more articles in the media than Amgen. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 54 mentions for Amgen. Amgen's average media sentiment score of 1.07 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	38 Very Positive mention(s)	8 Positive mention(s)	37 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive
Amgen	33 Very Positive mention(s)	8 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Amgen	20.96%	137.41%	13.28%

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.6%. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Amgen beats Regeneron Pharmaceuticals on 11 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Gilead Sciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 44 more articles in the media than Gilead Sciences. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 53 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.96 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	33 Very Positive mention(s)	7 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	38 Very Positive mention(s)	8 Positive mention(s)	37 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive

Gilead Sciences presently has a consensus target price of $157.93, indicating a potential upside of 21.29%. Regeneron Pharmaceuticals has a consensus target price of $794.83, indicating a potential upside of 4.22%. Given Gilead Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70

Gilead Sciences has a net margin of 30.99% compared to Regeneron Pharmaceuticals' net margin of 29.65%. Gilead Sciences' return on equity of 48.19% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.49	$8.51B	$7.34	17.74
Regeneron Pharmaceuticals	$15.53B	5.19	$4.50B	$40.46	18.85

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 14 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Moderna?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Regeneron Pharmaceuticals currently has a consensus price target of $794.83, suggesting a potential upside of 4.22%. Moderna has a consensus price target of $40.00, suggesting a potential downside of 27.03%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

In the previous week, Regeneron Pharmaceuticals had 61 more articles in the media than Moderna. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 36 mentions for Moderna. Moderna's average media sentiment score of 0.70 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	38 Very Positive mention(s)	8 Positive mention(s)	37 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive
Moderna	12 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Moderna's net margin of -143.55%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Moderna	-143.55%	-26.64%	-19.32%

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$15.53B	5.19	$4.50B	$40.46	18.85
Moderna	$2.20B	9.87	-$2.82B	-$8.15	N/A

Regeneron Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats Moderna on 13 of the 17 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 93 more articles in the media than Intellia Therapeutics. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 4 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.68 beat Intellia Therapeutics' score of 0.63 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	38 Very Positive mention(s)	8 Positive mention(s)	37 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Intellia Therapeutics' net margin of -597.04%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	22.05	-$412.69M	-$3.54	N/A
Regeneron Pharmaceuticals	$15.53B	5.19	$4.50B	$40.46	18.85

Intellia Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Intellia Therapeutics currently has a consensus price target of $20.19, suggesting a potential upside of 89.02%. Regeneron Pharmaceuticals has a consensus price target of $794.83, suggesting a potential upside of 4.22%. Given Intellia Therapeutics' higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

Regeneron Pharmaceuticals beats Intellia Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Vir Biotechnology's net margin of -638.88%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$64.69M	22.58	-$437.99M	-$3.13	N/A
Regeneron Pharmaceuticals	$15.53B	5.19	$4.50B	$40.46	18.85

Vir Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 90 more articles in the media than Vir Biotechnology. MarketBeat recorded 97 mentions for Regeneron Pharmaceuticals and 7 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.14 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	38 Very Positive mention(s)	8 Positive mention(s)	37 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vir Biotechnology currently has a consensus target price of $20.88, suggesting a potential upside of 141.05%. Regeneron Pharmaceuticals has a consensus target price of $794.83, suggesting a potential upside of 4.22%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

Regeneron Pharmaceuticals beats Vir Biotechnology on 11 of the 16 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REGN vs. The Competition

Export

Metric	Regeneron Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$80.63B	$3.53B	$6.85B	$12.46B
Dividend Yield	0.54%	3.78%	2.59%	10.11%
P/E Ratio	18.58	7.47	281.85	23.70
Price / Sales	5.19	1,216.39	571.46	79.29
Price / Cash	16.57	89.39	69.88	58.30
Price / Book	2.58	16.79	10.93	5.84
Net Income	$4.50B	-$12.44M	$3.49B	$336.16M
7 Day Performance	16.25%	-1.45%	-0.29%	0.08%
1 Month Performance	22.31%	-7.73%	-2.59%	-5.18%
1 Year Performance	39.81%	49.28%	66.20%	17.42%

Regeneron Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REGN Regeneron Pharmaceuticals	3.8967 of 5 stars	$762.63 +3.3%	$794.83 +4.2%	+33.1%	$80.63B	$15.53B	18.58	15,410	Trending News Earnings Report Dividend Announcement Analyst Forecast
AMGN Amgen	3.6428 of 5 stars	$366.05 -0.1%	$356.62 -2.6%	+28.6%	$197.56B	$36.75B	25.47	31,500	Trending News Upcoming Earnings Dividend Announcement Analyst Forecast
GILD Gilead Sciences	4.9095 of 5 stars	$130.34 +0.0%	$158.33 +21.5%	+14.4%	$161.83B	$29.44B	17.76	17,000	Trending News Upcoming Earnings Analyst Forecast Analyst Revision
MRNA Moderna	1.6067 of 5 stars	$58.07 -2.7%	$40.00 -31.1%	+80.2%	$23.04B	$2.20B	N/A	4,700	Trending News Earnings Report Options Volume
NTLA Intellia Therapeutics	3.3331 of 5 stars	$11.13 -3.0%	$20.19 +81.4%	-10.1%	$1.56B	$67.67M	N/A	600	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REGN) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Do analysts recommend REGN or AMGN?

Which has more volatility and risk, REGN or AMGN?

Which has higher valuation & earnings, REGN or AMGN?

Do institutionals & insiders have more ownership in REGN or AMGN?

Does the media favor REGN or AMGN?

Is REGN or AMGN more profitable?

Is REGN or AMGN a better dividend stock?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Which has more risk and volatility, GILD or REGN?

Does the media prefer GILD or REGN?

Do analysts prefer GILD or REGN?

Is GILD or REGN more profitable?

Which has stronger valuation & earnings, GILD or REGN?

Do insiders & institutionals have more ownership in GILD or REGN?

Is GILD or REGN a better dividend stock?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Do analysts rate REGN or MRNA?

Does the media refer more to REGN or MRNA?

Is REGN or MRNA more profitable?

Do insiders and institutionals believe in REGN or MRNA?

Which has preferable valuation & earnings, REGN or MRNA?

Which has more volatility & risk, REGN or MRNA?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Do insiders & institutionals hold more shares of NTLA or REGN?

Does the media favor NTLA or REGN?

Is NTLA or REGN more profitable?

Which has better valuation and earnings, NTLA or REGN?

Which has more volatility & risk, NTLA or REGN?

Do analysts recommend NTLA or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Is VIR or REGN more profitable?

Which has better earnings and valuation, VIR or REGN?

Which has more volatility & risk, VIR or REGN?

Does the media prefer VIR or REGN?

Do institutionals and insiders have more ownership in VIR or REGN?

Do analysts rate VIR or REGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools